Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BGCI

Financiado

Cerrado

Bacterial Ghost Cancer Immunotherapy A new standard in tumour therapy based on...

Bacterial Ghost Cancer Immunotherapy A new standard in tumour therapy based on the bacterial ghost platform technology MMalignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/ IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strat... ver más

31/07/2017

BIRD-C

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BIOTECH INNOVATION RESEARCH DEVELOPMENT AND C... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-07-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BIRD-C

50.00K€ | Lider

Proyectos interesantes

RIPECROP

Medical Technol...

Data Science

3M€ Cerrado

SPLITVAC

Medical Technol...

Data Science

173K€ Cerrado

CAR-TIME

Medical Technol...

Data Science

1M€ Cerrado

DCanVAX

Medical Technol...

Data Science

Cerrado

VACCIBIOME

Medical Technol...

Data Science

2M€ Cerrado

ICoMICS

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 5 meses Fecha Inicio: 2017-02-04
Fecha Fin: 2017-07-31

Líder del proyecto

BIOTECH INNOVATION RESEARCH DEVELOPMENT AND C... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto MMalignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/ IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strategies for cancer including surgery, chemotherapy and targeted molecular therapy still do not guarantee complete elimination of the disease. In addition, cancer cells exhibited high capability to escape from immunosurveillance after applied treatment which was confirmed with frequently occurred relapse of disease. BIRD-C have developed Bacterial Ghost Cancer Immunotherapy (BGCI) - a novel personalised medicine approach towards vaccination against tumours. BIRD-C’s therapeutic cancer vaccines are based on personalised dendritic cells-based cancer immunotherapy that targets the tumour microenvironment using Bacterial Ghosts (BGs), the proprietary platform technology of BIRD-C. The tumour therapy strategy is to (re)stimulate the patient immune system to revert the tumour evasion and build strong humoral and cellular immune responses against patient-specific tumour antigens. Obtained results show that BGCI can generate effective response to tumours and indicate novel prospective methods for cellular cancer immunotherapy. This approach has been tested in a form of advanced personalised cancer therapy and has improved the survival of patients with solid tumours. During the project, BIRD-C will develop the manufacturing procedure and commercial scale-up strategy and also conduct a multi-centre trial with patients affected by various forms of cancer at different stages of progression to determine the tolerability and effectiveness of the treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores